Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Galapagos' CF Candidate Shows Potential In Phase II Study

Published 11/19/2017, 09:44 PM
Updated 07/09/2023, 06:31 AM

Galapagos NV (NASDAQ:GLPG) announced positive top-line data from a phase II study – ALBATROSS – evaluating its cystic fibrosis transmembrane conductance (“CFTR”) corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function.

So far this year, Galapagos’shares have outperformed the industry. The stock has gained 41.5% compared with an increase of 1.5% registered by the industry.

The phase II study evaluated two once-daily doses – 150 mg and 300 mg – of the candidate in CF patients who have one gating mutation and an F508del mutation and were on long-term stable treatment with Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) CF drug, Kalydeco. Treatment with Kalydeco was continued during the course of the study.

The study achieved its primary objective of safety and was well tolerated in the patient population. Data also showed an improvement of 2.2% in mean percent predicted FEV1 (a measure of lung function) compared to baseline in 300 mg arm of the study.

Meanwhile, Vertex is also developing a combination therapy, tezacaftor plus Kalydeco, in similar indication.

Apart from GLPG2222, Galapagos is also developing GLPG2737, a CFTR regulator, in a phase I study and GLPG1837, a CFTR potentiator, in a phase II study in CF patients. All three candidates are being developed in partnership with AbbVie Inc. (NYSE:ABBV) . The company has a diverse pipeline with candidates being developed in several other indications including atopic dermatitis, psoriatic arthritis, uveitis and lupus membranous nephropathy among others.

Zacks Rank & Stock to Consider

Galapagos carries a Zacks Rank #3 (Hold).

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is a better-ranked health care stock, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Sucampo’s earnings per share estimates have increased from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters with an average beat of 15.63%.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



AbbVie Inc. (ABBV): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Galapagos NV (GLPG): Free Stock Analysis Report

Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.